Table 1.
Summary of clinicopathologial features of patients in GCB and non-GCB groups
| Characteristics | GCB and non-GCB groups, n | BACH2 expression |
Hans' criteria |
||||
|---|---|---|---|---|---|---|---|
| High, n | Low, n | P | GCB, n | non-GCB, n | P | ||
| Overall | 76 | 40 | 36 | 38 | 38 | ||
| Clinical information | |||||||
| Median age (range) [year] | 61 (20–80) | 61 (20–80) | 61.5 (42–74) | 0.523 | 61 (20–79) | 61 (38–80) | 0.733 |
| Age ≥60 years | 45 | 22 | 23 | 0.431 | 23 | 22 | 0.815 |
| Male/Female | 48/28 | 26/14 | 22/14 | 0.726 | 24/14 | 24/14 | 1 |
| Performance status 0–1/2–4 | 59/17 | 31/9 | 28/8 | 0.977 | 28/10 | 31/7 | 0.409 |
| Clinical stage I–II/III–IV | 44/32 | 21/19 | 23/13 | 0.315 | 23/15 | 21/17 | 0.642 |
| The presence of B symptoms | 12 | 7 | 5 | 0.666 | 5 | 7 | 0.529 |
| The presence of extranodal lesions | 14 | 10 | 4 | 0.119 | 10 | 4 | 0.0758 |
| IPI score 0–2/3–5 | 51/26 | 25/15 | 26/10 | 0.368 | 25/13 | 26/12 | 0.807 |
| Median LDH (range) [IU/L] | 275 (126–2116) | 285.5 (148–2116) | 274 (126–1964) | 0.534 | 279.5 (144–2116) | 274 (126–1476) | 0.237 |
| Median sIL-2R (range) [U/mL] | 1362 (234–22 564) | 1512.5 (257–21 373) | 1229.5 (234–22 564) | 0.832 | 1190 (234–21 373) | 2110 (309–22 564) | 0.157 |
| Pathological features | |||||||
| GCB/non-GCB | 38/38 | 21/19 | 17/19 | 0.646 | — | — | — |
| Positive MUM1 | 38/38 | 19 | 18 | 0.828 | 2 | 35 | <0.001 |
| Positive BCL2 | 52 | 29 | 23 | 0.420 | 23 | 29 | 0.139 |
| MIB-1 index ≥ 90% | 17 | 12† | 5 | 0.0811 | 8† | 9 | 0.831 |
| High MYC expression | 37 | 24 | 13 | 0.0375 | 22 | 15 | 0.246 |
| Treatment | |||||||
| R-CHOP (and related regimens) | 76 | 40 | 36 | NA | 38 | 38 | NA |
| Others | 0 | 0 | 0 | 0 | 0 | ||
| Outcome | 0.378 | ||||||
| Complete response | 58 | 28 | 30 | 0.0842 | 28 | 30 | |
| Partial response | 13 | 7 | 6 | 6 | 7 | ||
| Stable disease | 0 | 0 | 0 | 0 | 0 | ||
| Progressive disease | 5 | 5 | 0 | 4 | 1 | ||
| Relapse | 14 | 9 | 5 | 0.334 | 4 | 10 | 0.0758 |
| 3-year OS [%] | 80.8 | 71.7 | 91.3 | 0.0256 | 75.9 | 86.4 | 0.265 |
| 3-year PFS [%] | 71.0 | 62.5 | 80.3 | 0.0681 | 74.5 | 67.5 | 0.636 |
| Median follow-up time (range) [month] | 33.3 (0.2–66.3) | 31.7 (0.2–66.3) | 33.5 (4.7–64.7) | 0.775 | 31.1 (0.2–66.3) | 35.8 (3.3–64.7) | 0.623 |
†
In one case MIB-1 index was not assessed.
IPI, international prognostic index; LDH, lactate dehydrogenase; NA, not available; OS, overall survival; PFS, progression-free survival; sIL-2R, soluble inteleukin-2 receptor.